Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjunctive Allogeneic MSCs for Treatment-resistant Bipolar Depression
NCT03522545Phase 1Recruiting
- Sponsor
- UTHealth Houston
- Start
- Apr 2022
- Primary completion
- Dec 2026
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of allogeneic bone marrow-derived multipotent mesenchymal stromal cells in bipolar disorder (BD), sponsored by UTHealth Houston. Primary endpoint: Montgomery-Åsberg Depression Rating Scale at 26 weeks. Started Apr 2022; status: recruiting.
02
Drugs
allogeneic bone marrow-derived multipotent mesenchymal stromal cells
03
Conditions
bipolar disorder (BD)
Beyond the preview
Go deeper on NCT03522545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03522545.